Phase 1 Solid Tumor, Adult trials recruiting now

All Solid Tumor, Adult trials, every phase

Other phases for Solid Tumor, Adult

Phase 1 Solid Tumor, Adult trials

• 64Cu-GRIP B in Patients With Advanced Malignancies
  NCT05888532 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
  NCT06228326 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
  NCT06244771 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
  NCT06586957 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 38 locations
• A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
  NCT05669430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of VET3-TGI in Patients With Solid Tumors
  NCT06444815 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
  NCT06598007 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
  NCT04913285 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 48 locations
• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
  NCT06682793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
  NCT06051695 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
  NCT06326411 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
  NCT03686124 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer
  NCT06917079 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• COAST Therapy in Advanced Solid Tumors and Prostate Cancer
  NCT05036226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
  NCT06337084 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
  NCT06617169 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
  NCT04842812 · Phase: Phase 1 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 2 locations
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• GPC3/Mesothelin-CAR-γδT Cells Against Cancers
  NCT06196294 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
  NCT05779917 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
  NCT06625775 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
  NCT07139990 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
  NCT05856981 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
  NCT06218914 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
  NCT06398418 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 2 locations
• Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
  NCT06506643 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
  NCT04282044 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
  NCT03778814 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.